Inhibrx Biosciences, Inc.: Q4 FY2025 earnings call
What management said about Q4 FY2025, from the documents filed with the SEC on 19 March 2026: press release. Guidance figures: 4 new, 1 kept. The quarter’s numbers.
Key takeaways
- Fourth-quarter net loss narrowed: Net loss was $32.8 million, or $2.11 per share, against $47.9 million, or $3.09 per share, in the fourth quarter of 2024. Source
- Quarterly R&D spend fell: Fourth-quarter R&D was $25.3 million, against $33.4 million. The decrease was tied to lower ozekibart registration-trial clinical costs and lower contract manufacturing expense. Source
- Ozekibart met primary endpoint: The ozekibart registrational trial in chondrosarcoma met its primary endpoint, with a median PFS improvement over placebo that the release calls statistically significant and clinically meaningful.
- Cash fell over the year: Cash and cash equivalents were $124.2 million at December 31, 2025, against $152.6 million a year earlier and $153.1 million at September 30, 2025. Source
- Equity down to $8.0 million: Stockholders' equity was $8.0 million at December 31, 2025, down from $133.6 million a year earlier and $36.8 million at September 30, 2025. Source
- Two programs after the sale: Following the sale of INBRX-101 to Sanofi, the company describes itself as having two programs in ongoing clinical trials. Source
“the biopharmaceutical company now has two programs in ongoing clinical trials”
Inhibrx Biosciences, Inc., press release
Guidance
| Area | Period | Figure | Against last quarter |
|---|---|---|---|
| Ozekibart BLA submission Source | early second quarter 2026 | early in the second quarter of 2026 | Kept |
| Ozekibart colorectal PFS data Source | second quarter 2026 | second quarter of 2026 | New |
| INBRX-106 HNSCC interim ORR data Source | second quarter 2026 | second quarter of 2026 | New |
| INBRX-106 HNSCC PFS data Source | fourth quarter 2026, at ESMO 2026 Congress | fourth quarter of 2026 | New |
| FDA meeting on accelerated approval Source | second half 2026 | second half of 2026 | New |
What changed from last quarter
- New: On March 18, 2026, the company amended its loan agreement with Oxford Finance and received $75.0 million of gross proceeds. Source
- New guidance: Dated timing for INBRX-106 interim ORR data in HNSCC (second quarter 2026) appears in this release. The prior release gave no timing for this data. Source
- Guidance kept: The prior release gave BLA submission timing as the second quarter of 2026. This release states early in that quarter.
Results for the quarter and year
- Fourth-quarter net loss narrowed: Net loss was $32.8 million, or $2.11 per share, against $47.9 million, or $3.09 per share, in the fourth quarter of 2024. Source
- No license revenue in quarter: The company reported no license fee revenue in the fourth quarter of 2025, against $0.1 million a year earlier. Fiscal 2025 license fee revenue was $1.3 million. Source
- Fiscal year moved to a loss: Fiscal 2025 net loss was $140.1 million, or $9.04 per share. Fiscal 2024 showed net income of $1.7 billion, which included the 101 Transaction gain. Source
Operating expenses
- Quarterly R&D spend fell: Fourth-quarter R&D was $25.3 million, against $33.4 million. The decrease was tied to lower ozekibart registration-trial clinical costs and lower contract manufacturing expense. Source
- Full-year R&D spend declined: Fiscal 2025 R&D was $113.0 million, against $203.7 million in fiscal 2024. Lower CDMO spend on ozekibart and INBRX-106, and lower expense after the 101 Transaction, contributed. Source
- Legal costs fell away in quarter: Fourth-quarter G&A was $5.6 million, against $16.7 million. Prior-period legal services tied to proceedings that have concluded were the main driver of the decrease. Source
- Fiscal 2024 deal costs absent: Fiscal 2025 G&A was $23.3 million, against $127.9 million. Fiscal 2024 included one-time 101 Transaction costs and option acceleration expense. Source
“as the trial approached completion of enrollment ahead of our data readout in October 2025”
Inhibrx Biosciences, Inc., press release
Pipeline and clinical programs
- Ozekibart met primary endpoint: The ozekibart registrational trial in chondrosarcoma met its primary endpoint, with a median PFS improvement over placebo that the release calls statistically significant and clinically meaningful.
- Expansion cohorts showed high response: Interim data from colorectal cancer and Ewing sarcoma expansion cohorts were described as showing high response and disease control rates in heavily pretreated patients.
- Two clinical candidates listed: The current clinical pipeline comprises ozekibart and INBRX-106. Both use multivalent formats in which valency is optimized to produce the intended agonist function. Source
Cash, debt and equity
- Cash fell over the year: Cash and cash equivalents were $124.2 million at December 31, 2025, against $152.6 million a year earlier and $153.1 million at September 30, 2025. Source
- Long-term debt now on balance sheet: Long-term debt was $100.6 million at December 31, 2025, against none at December 31, 2024. Debt from the prior period was extinguished in connection with the 101 Transaction. Source
- Equity down to $8.0 million: Stockholders' equity was $8.0 million at December 31, 2025, down from $133.6 million a year earlier and $36.8 million at September 30, 2025. Source
“Ozekibart met its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo.”
Inhibrx Biosciences, Inc.
Corporate background and the 101 Transaction
- Two programs after the sale: Following the sale of INBRX-101 to Sanofi, the company describes itself as having two programs in ongoing clinical trials. Source
- Spin-off completed May 2024: The Inhibrx business was spun off in May 2024, concurrently with the sale of INBRX-101 to Sanofi by the Former Parent. Source
- Most shares distributed to holders: Inhibrx, Inc. distributed 92% of the issued and outstanding shares of Inhibrx to holders of its common stock as part of the restructuring. Source
Other income and expense
- Quarterly other expense: Fourth-quarter other expense was $1.9 million, against other income of $2.1 million a year earlier. Other income reflects interest on sweep and money market balances. Source
- Fiscal other expense from debt interest: Fiscal 2025 other expense was $5.0 million. Interest expense of $12.2 million on the $100.0 million debt balance was partly offset by interest income. Source
- Fiscal 2024 gain components: The fiscal 2024 gain combined consideration for common stock, warrants and options, debt extinguishment, assumed assets and liabilities, and transaction costs paid by the Acquirer. Source
Coming up, as management said on 19 March 2026
- Ozekibart BLA submission: The company expects to submit the ozekibart BLA for chondrosarcoma to the FDA early in the second quarter of 2026. Source
- Colorectal PFS data readout: PFS data from the Phase 1/2 colorectal cancer expansion cohort are planned for announcement in the second quarter of 2026. Source
- INBRX-106 interim ORR readout: Interim ORR data from the randomized Phase 2/3 HNSCC trial with pembrolizumab are planned for announcement in the second quarter of 2026. Source
- FDA meeting on accelerated approval: The company plans to meet with the FDA on accelerated approval for Ewing sarcoma and fourth-line colorectal cancer in the second half of 2026. Source
- INBRX-106 PFS data at ESMO: PFS data from the HNSCC Phase 2/3 trial with pembrolizumab are planned for the fourth quarter of 2026, at the ESMO 2026 Congress. Source
Figures management reported
| Figure | Reported |
|---|---|
| R&D expense, fourth quarter 2025 Source | $25.3 million |
| R&D expense, fiscal 2025 Source | $113.0 million |
| Trial readout | Ozekibart met primary endpoint in chondrosarcoma (October 2025) |
Earlier plans management reported on
- Not stated: The prior release gave second quarter 2026 for the BLA. This release narrows the timing to early in that quarter; no status word is used.
Other quarters
Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.